Damian Garde
Eli Lilly and Merck are expanding their oncology partnership to study a combination of the former's top cancer prospect with the latter's blockbuster immunotherapy.
FierceBiotech ...
Damian Garde
Amgen submitted its copy of AbbVie's blockbuster Humira to European regulators, angling to siphon revenues from the world's top-selling drug as rivals develop biosimilars ...
Alok Saboo
FiercePharma News
John Carroll
Doug Williams is now happy to reveal just why he stepped aside four months ago as R&D chief of Biogen. Last July, Williams signed on as "employee number one" ...
Eric Palmer
Merck & Co. is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics ...
Damian Garde
Daiichi Sankyo picked up the FDA's breakthrough therapy designation for a Phase III cancer drug, putting it in line for preferential access to agency experts as it ...
Eric Palmer
Allergan has been trying for months to resolve bribery allegations that came with its $ 8.5 billion buyout of Warner Chilcott and now will do that with a plea deal ...
Emily Wasserman
Merck's Keytruda got a green light from the U.K.'s cost effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as ...
John Carroll
FierceBiotech News
Beth Snyder Bulik
Some heavy-hitting HIV activists have signed on to Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with ...
John Carroll
FierceBiotech News
Damian Garde
Antibiotics biotech Nabriva Therapeutics executed a $ 92.3 million IPO, pricing well below its projected range but scraping together the funds it needs to start a Phase ...